https://bio.nikkeibp.co.jp/atcl/news/p1/25/08/05/13606/

Sumitomo Pharma and RACTHERA, a joint venture between Sumitomo Pharma and Sumitomo Chemical, have filed an application for manufacturing and marketing approval in Japan for allogeneic iPS cell-derived dopaminergic progenitor cells (generic name: raguneprocel).

Dopaminergic neural progenitor cells are induced and generated by Kyoto University or Sumitomo Pharma from the allogeneic iPS cell line “QHJI01s04” provided by the Kyoto University iPS Cell Research and Application Foundation (CiRA_F). When transplanted into the cerebral putamen of Parkinson’s disease patients using stereotactic brain surgery, the cells are expected to take root in the patient’s brain, produce dopamine, and demonstrate therapeutic effects.

In April 2025, Kyoto University Hospital announced that it had obtained data suggesting a certain degree of safety and efficacy in an investigator-initiated clinical trial of raguneprocel.